Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
ResMed Inc. (RMD) director files Form 4 for planned stock sale. Director Jan De Witte reported selling 2,055 shares of ResMed common stock on 11/25/2025 at a price of $255 per share. After this transaction, De Witte beneficially owns 4,261 shares, held directly.
The sale was coded as an "S" transaction and was carried out under a Rule 10b5-1 trading plan adopted on August 18, 2025, indicating it was pre-arranged under preset instructions rather than a discretionary, one-off trade.
ResMed Inc. director Nicole Mowad-Nassar reported equity transactions involving the company’s stock. As a member of the board of directors, she filed a Form 4 as a single reporting person.
On 11/24/2025, she was granted stock options on 1,331 shares of ResMed common stock at an exercise price of $250.52 per share. These options become exercisable on the earlier of November 11, 2026, or the date of the first annual meeting of stockholders following the grant date. The filing also shows a disposition of 777 shares of ResMed common stock, reflecting routine personal trading activity by a director.
ResMed Inc. insider plans sale of common shares under Rule 144. The notice covers a proposed sale of 2,055 common shares through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $524,025.00. The issuer has 145,966,294 common shares outstanding. The shares derive from restricted stock vesting awards granted as compensation on 11/11/2021 and 11/11/2024.
During the past three months, the same seller, Jan De Witte, sold 487 common shares on 11/11/2025 for gross proceeds of $121,871.75. By signing the notice, the seller represents that he does not know any material adverse information about ResMed’s current or prospective operations that has not been publicly disclosed.
ResMed Inc. (RMD) filed a Form 4 disclosing that its Chief Product Officer acquired 1,848 shares of common stock on 11/20/2025. These shares came from performance-based restricted stock units that were originally granted on November 16, 2022 and were earned when the compensation and leadership development committee certified that the performance targets were met.
After this transaction, the officer beneficially owns 29,028 shares of ResMed common stock in direct ownership. The transaction was reported as an acquisition at a price of $0, reflecting the vesting of equity compensation rather than an open-market purchase.
ResMed Inc. (RMD) reported a director equity grant on a Form 4. On 11/20/2025, a company director acquired 1,073 shares of ResMed common stock through a stock award at a stated price of $0 per share, reflecting a grant of restricted stock units.
After this transaction, the reporting person beneficially owned 5,118 shares of ResMed common stock in direct ownership. The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, aligning the director’s compensation with shareholder interests over that period.
ResMed Inc. (RMD) reported an insider equity award for director Nicole Mowad-Nassar on a Form 4. On 11/20/2025, she received 536 shares of ResMed common stock as a grant of restricted stock units at a stated price of $0 per share, reflecting a stock-based award rather than an open-market purchase. Following this transaction, she beneficially owned 777 shares directly.
The filing notes that these restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders held in the year following the grant date. This is a routine director compensation transaction and does not involve any derivative securities.
ResMed Inc. director Desney Tan reported receiving a new equity award from the company. On 11/20/2025, he acquired 1,073 shares of ResMed common stock through a grant priced at $0, increasing his directly owned stake to 6,002 shares after the transaction.
The award is in the form of restricted stock units (RSUs), which are shares that Tan will receive once they vest. These RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, meaning the shares are subject to a service-based vesting condition tied to time and board tenure.
ResMed Inc. (RMD) reported that director Harjit Gill received an equity award in the form of 1,073 restricted stock units (RSUs) of ResMed common stock on 11/20/2025. The RSUs were granted at a price of $0 per unit, reflecting a typical director equity grant rather than an open‑market purchase.
After this award, Gill beneficially owns 10,940 shares of ResMed common stock. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to continued board service over roughly a one‑year cycle.
ResMed Inc. (RMD) reported an equity grant to director Karen Drexler. On 11/20/2025, she acquired 1,073 shares of ResMed common stock through a grant of restricted stock units at a stated price of $0 per share.
The restricted stock units vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date. After this award, Karen Drexler beneficially owned 10,602 shares directly.
ResMed Inc. (RMD) director Carol Burt reported a grant of 1,073 shares of ResMed common stock in the form of restricted stock units. These RSUs were awarded on 11/20/2025 at a price of $0 per share, reflecting a typical equity compensation grant for a board member rather than an open-market purchase.
Following this award, she reported 2,156 shares of ResMed common stock held directly and an additional 16,660 shares held indirectly through the Carol Burt Hilliard Trust. The RSUs vest in full on the earlier of 11/11/2026 or the annual meeting of stockholders in the year following the grant date, tying the equity award to her continued board service.